ADRENERGIC REGULATION OF HUMAN PROSTATE GROWTH

人类前列腺生长的肾上腺素调节

• 批准号: 6381347
• 负责人: VICTOR K LIN
• 金额: $ 23.45万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-05-01 至 2003-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6381347
• 关键词: alpha adrenergic agent; alpha adrenergic receptor; benign prostate hyperplasia; cell growth regulation; clinical research; cytoskeletal proteins; human subject; immunocytochemistry; pathologic process; prostate; protein isoforms; protein structure function; smooth muscle; tissue /cell culture

DESCRIPTION (Adapted from the Applicant's Abstract): Benign prostate hyperplasia (BPH) is primarily a disease of stromal proliferation. Smooth muscle (SM) is a major component of prostatic stroma. Therefore, it is likely that the progression of BPH requires smooth muscle proliferation. In many smooth muscle tissues, the state of contractile protein gene regulation is modulated during proliferation, with a loss of normal contractile proteins during active growth and a re-acquisition of contractile proteins once growth has been arrested. Little is known regarding the phenotypic modulation of stromal SM cells during the initiation and progression of BPH. In addition, the impact of therapy, specifically a blockade, on the SM phenotype is unknown. In preliminary studies, they have demonstrated that men with established BPH have evidence of a smooth muscle de-differentiation process, compatible with past but not ongoing SM proliferation. In addition, they have demonstrated that a blockade significantly affects the SM phenotype. They propose to characterize the expression of SM phenotypic markers, including myosin heavy chain and caldesmon, to determine whether the smooth muscle phenotype is altered during the natural history and progression of BPH. In addition, they will expand or preliminary studies to determine to what extent the SM phenotype is regulated by alpha adrenergic signal transduction pathways. They will utilize two unique tissue banks for these studies. First, a large number of normal and hyperplastic prostates from men of a variety of age groups banked as part of the UT Southwestern NIH O'Brien Center Repository and from the NIH Medical Therapy of Prostate Symptoms (MTOPS) clinical trial which will permit longitudinal observation of single patients in correlation with clinical outcome. Quantitative RT_PCR, immunohistochemical and morphometric analysis will be utilized to address the following specific aims: (1) to establish and validate methods of archived tissue analysis suitable for a multi-center trial; (2) to define changes in the SM phenotype which occur during the natural history of BPH; (3) to determine whether the SM phenotypes is modulated by alpha adrenergic signals; (4) using a prostate SM culture system, elucidate the regulatory role of alpha1A adrenergic stimulation in prostatic SM growth and differentiation.

描述（改编自申请人的摘要）：良性前列腺 增生（BPH）主要是基质增殖的疾病。 光滑的 肌肉（SM）是前列腺基质的主要组成部分。 因此，是 BPH的进展可能需要平滑的肌肉增殖。 在 许多平滑肌组织，收缩蛋白基因调节状态 在增殖过程中进行调制，损失正常收缩 积极生长期间的蛋白质和收缩蛋白的重新收购 一旦增长被捕。 关于表型知之甚少 在BPH的启动和进展过程中，基质SM细胞的调节。 另外，治疗的影响，特别是封锁的影响 表型未知。 在初步研究中，他们证明了 BPH已建立的男性有平滑肌肉脱不同的证据 过程，与过去但不在进行的SM扩散兼容。 在 此外，他们证明了封锁显着影响 SM表型。 他们建议表征SM表型的表达 标记，包括肌球蛋白重链和Caldesmon，以确定是否是否 平滑肌表型在自然史上发生了变化， BPH的进展。 此外，它们将扩展或初步研究 确定SM表型在多大程度上受α肾上腺素的调节 信号转导途径。 他们将利用两个独特的组织库进行 这些研究。 首先，大量的正常和增生前列腺 来自各种年龄段的男人，作为UT西南部的一部分 NIH O'Brien Center存储库以及前列腺的NIH医疗疗法 症状（MTOPS）临床试验，该试验将允许纵向观察 与临床结局相关的单身患者。 定量 RT_PCR，免疫组织化学和形态计量分析将用于 解决以下特定目的：（1）建立和验证方法 存档的组织分析适用于多中心试验； （2）定义 在BPH自然病史期间发生的SM表型的变化； （3）确定SM表型是否由α肾上腺素调节 信号； （4）使用前列腺SM培养系统，阐明调节 α1a肾上腺素能刺激在前列腺SM生长中的作用 分化。